Literature DB >> 7346748

Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants.

K Minagawa, H Miura, K Chiba, T Ishizaki.   

Abstract

Phenobarbital pharmacokinetics after a single intramuscular dose of approximately 10 mg/kg of phenobarbital sodium or acid were studied in twelve infants with febrile convulsions. The mean peak time after phenobarbital sodium (0.92 hr) was significantly (p less than 0.01) shorter than that after phenobarbital acid (5.83 hr), whereas the mean peak levels (16.2 vs 13.8 microgram/ml) did not reach statistical difference (p less than 0.2) between both dosage forms. The values of the absorption rate constant and the area under the curves calculated from 0- to up to 6-hr periods were significantly higher (P less than 0.001 to 9.005) after the sodium form. There were no significant differences in such parameters as t1/2, Vd/F, and C1/F between the two preparations. The overall mean values of these variables were: t1/2, 64.0 hr, Vd/F, 0.667 1/kg, and C1/F, 0.136 m1/min/kg. Some delay in rising phenobarbital concentration in cerebrospinal fluid (CSF) as compared with that in plasma after phenobarbital sodium was observed, though the absolute values of phenobarbital concentrations in CSF were similar from both dosage forms around the time when peak plasma levels were attained.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7346748

Source DB:  PubMed          Journal:  Pediatr Pharmacol (New York)        ISSN: 0270-322X


  3 in total

1.  Determination of phenobarbitone population clearance values for South African children.

Authors:  J H Botha; A L Gray; R Miller
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 2.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.